Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Clinical Success Achieved in Second Cohort of Patients
PRINCETON, N.J., Jan. 4, 2024 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and...

Related Keywords

Sudan ,Richard Straube ,Christopherj Schaber ,Twitter ,Prnewswire Soligenix Inc ,Nasdaq ,Drug Administration ,World Health Organization ,Us Congress ,Linkedin ,Our Public Health Solutions ,Defense Threat Reduction Agency ,Us Development ,Biomedical Advanced Research ,Development Authority ,European Medicines Agency ,National Institute Of Allergy ,Soligenix Inc ,Exchange Commission ,Clinical Success Achieved ,Second Cohort ,Investigator Global Assessment ,Psoriasis Activity ,Severity Index ,Chief Medical Officer ,Senior Vice President ,Chief Executive Officer ,Fluorescent Light Activated Synthetic Hypericin ,Global Report ,Public Health Solutions ,National Institute ,Infectious Diseases ,Project Bioshield ,Priority Review Voucher ,Markets ,